Skip to main content

Table 3 Characteristics at baseline of patients in the validation cohort

From: Establishment and validation of a prognosis nomogram for MIMIC-III patients with liver cirrhosis complicated with hepatic encephalopathy

Variable

Alive (n = 105)

Dead (n = 81)

P value

Demographics

 Age, year

54.49 (12.51)

56.87 (12.34)

0.364

 Gender, n(%)

  

0.330

  Men

72 (68.6)

50 (61.7)

 

  Women

33 (31.4)

31 (38.3)

 

 weight, kg

84.00 (28.00)

80.00 (26.00)

0.303

Etiology of cirrhosis(%)

  

0.230

 Alcoholic cirrhosis of liver

66 (62.9)

45 (55.6)

 

 Cirrhosis of liver without mention of alcohol

37 (35.2)

36 (44.4)

 

 Biliary cirrhosis

2 (1.9)

0 (0.0)

 

Firstday vital signs in ICUa

 Mean heart rate, beats/min

82.54 (22.83)

84.00 (23.44)

0.335

 MAP, mmHg

74.84 (15.32)

68.67 (11.88)

0.001

 Mean respiratory rate, breaths/min

17.37 (4.48)

18.64 (5.73)

0.069

 Mean SpO2,%

98.15 (2.41)

97.39 (2.65)

0.002

 Mean temperature, °C

36.71 (0.78)

36.35 (0.84)

0.002

Complication

 Alcohol abuse, n(%)

60 (57.1)

47 (58.0)

0.904

 Chronic pulmonary, n(%)

17 (16.2)

21 (25.9)

0.103

 Cardiac arrhythmias, n(%)

12 (11.4)

20 (24.7)

0.017

 Coagulopathy, n(%)

53 (50.5)

50 (61.7)

0.126

 Congestive heart failure, n(%)

10 (9.5)

19 (23.5)

0.009

 Diabetes, n(%)

28 (26.7)

28 (34.6)

0.244

 Hypertension, n(%)

32 (30.5)

33 (40.7)

0.145

 Renal failure, n(%)

21 (20.0)

23 (28.4)

0.182

First laboratory testsb

 Lactate, mmol/L

2.20 (1.25)

2.30 (1.90)

0.258

 ALT,IU/L

34.00 (35.00)

47.00 (73.00)

0.039

 Albumin, g/dL

2.90 (0.80)

2.70 (0.80)

0.004

 ALP,IU/L

127.00 (94.00)

137.00 (94.00)

0.111

 Anion gap, mEq/L

14.00 (5.00)

15.00 (6.00)

0.436

 AST,IU/L

61.00 (55.00)

96.00 (122.00)

0.016

 Bicarbonate, mEq/L

22.00 (6.00)

21.00 (8.00)

0.314

 Total bilirubin, mg/dL

3.50 (4.70)

6.10 (15.3)

 < 0.001

 Total calcium, mg/dL

8.50 (1.00)

8.20 (1.10)

0.172

 Chloride, mEq/L

102.00 (11.00)

100.00 (11.00)

0.055

 Creatinine, mg/dL

1.20 (1.40)

1.60 (2.00)

0.013

 Magnesium, mg/dL

2.00 (0.60)

2.10 (0.60)

0.030

 Potassium, mEq/L

4.20 (1.20)

4.70 (1.20)

0.003

 Sodium, mEq/L

135.00 (9.00)

134.00 (10.00)

0.015

 Urea Nitrogen, mg/dL

28.00 (32.00)

36.00 (32.00)

0.005

 Hemoglobin, g/dL

10.20 (2.20)

10.30 (2.40)

0.728

 INR

1.70 (0.50)

2.00 (1.10)

 < 0.001

 PLT,K/uL

98.00 (75.00)

96.00 (80.00)

0.911

 PT, sec

16.70 (4.10)

21.00 (9.60)

 < 0.001

 PTT, sec

36.50 (12.10)

43.90 (13.20)

 < 0.001

 RDW,%

16.70 (3.30)

17.80 (4.00)

0.029

 WBC,K/uL

7.20 (4.8)

9.40 (8.50)

0.001

 RBC, m/uL

3.07 (0.84)

3.13 (0.71)

0.958

Therapeutic measure

 Albumin use, n(%)

45 (42.9%)

47 (58.0%)

0.040

 Furosemide use, n(%)

51 (48.6%)

42 (51.9%)

0.657

 PPI use, n(%)

84 (80.0%)

58 (71.6%)

0.182

 PAD, n(%)

41 (39.0%)

48 (59.3%)

0.006

Severity score

 SOFA

8.00 (4.00)

10.00 (5.00)

0.001

 MELD

21.32 (10.99)

30.99 (12.41)

 < 0.001

Others

 Urine Outputc, ml

1095.00 (1447.00)

816.00 (1186.00)

0.003

  1. Categorical variables were presented as frequency (percentage), parametric continuous variables were presented as median (interquartile)
  2. MAP Mean arterial pressure, SpO2 Blood oxygen saturation, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ALP Alkaline phosphatase, INR International normalized ratio, PT Prothrombin time, PTT Partial thromboplastin time, PLT Platelet, RDW Red cell distribution width, WBC White blood cells count, RBC Red blood cell count, PPI.use Proton pump inhibitors use, PAD Percutaneous abdominal drainage, SOFA Sequential organ failure assessment, MELD Model for end-stage liver disease
  3. aVital signs were calculated as mean value during the first 24 h since ICU admission of each included patients
  4. bThe laboratory tests recorded the first value after admission
  5. cThe urine output was recorded during the first 24 h in the ICU
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us